Results 121 to 130 of about 539,919 (309)
Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods
Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled; Michael Gilligan, John R. Mills, Paulina Vargas, Naveen K. Paramasivan, Connie E. Lesnick, Eati Basal, Surendra Dasari, James P. Fryer, Shannon R. Hinson, Joseph Laporta, Amy Espinal, Dennis Fitzgerald, Carolina Garcia, Anna E. Morenkova, Paola Pergami, Anna Shah, Andrew Knight, Reghann LaFrance Corey, Vanda A. Lennon, Anastasia Zekeridou, Sean J. Pittock, Divyanshu Dubey, Andrew McKeon +22 morewiley +1 more sourceA minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types
Nature CommunicationsIdentifying tumor-specific T cell clones that mediate immunotherapy responses remains challenging. Mutation-associated neoantigen (MANA) -specific CD8+ tumor-infiltrating lymphocytes (TIL) have been shown to express high levels of CXCL13 and CD39 (ENTPD1)Zhen Zeng, Tianbei Zhang, Jiajia Zhang, Shuai Li, Sydney Connor, Boyang Zhang, Yimin Zhao, Jordan Wilson, Dipika Singh, Rima Kulikauskas, Candice D. Church, Thomas H. Pulliam, Saumya Jani, Paul Nghiem, Suzanne L. Topalian, Patrick M. Forde, Drew M. Pardoll, Hongkai Ji, Kellie N. Smith +18 moredoaj +1 more sourceMortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19 [PDF]
, 2022 Csilla Várnai, Claire Palles, Roland Arnold, Helen Curley, Karin Purshouse, Vinton W.T. Cheng, Stephen Booth, Naomi Campton, Graham P. Collins, D.J. Hughes, Austin Kulasekararaj, Alvin Lee, Anna Olsson‐Brown, Archana Sharma‐Oates, Mieke Van Hemelrijck, Lennard Y. W. Lee, Rachel Kerr, Gary Middleton, Jean‐Baptiste Cazier, S. Pugh, Pippa Corrie, Ahmed Bedair, Madeleine Hewish, Pauline Leonard, Jack Illingworth, Stephen P. Hibbs, Nicolaos Diamantis, Samah Massalha, Claire Fuller, Caroline Usbourne, Duncan C. Gilbert, Jennifer Davies, Tom Newsom‐Davis, Rachel Sharkey, Rebecca Lee, Ann Tivey, Rohan Shotton, Clare Griffin, Laura Horsley, Simon Shamas, Joseph J. Sacco, Madbuba Choudhury, Jillian Noble, Heather Shaw, Rachel Bolton, Ana Ferreira, Peter Hall, Paul Ramage, Jaishree Bhosle, Alison Massey, Michaela Hill, Leena Mukherjee, Aisha Ghaus, Sarah Derby, Sean Brown, Sarah Lowndes, Saorise Dolly, Beth Russell, Charlotte Moss, Daniel J. Müller, Annet Pillai, Shakeel Lowe, Lucy Cook, Christopher Scrase, R. Jyothirmayi, Ruth Board, Stephanie Cornthwaite, Shefail Parikh, Emma Cattell, Nicola Cox, Abigail Gault, Sam Moody, Caroline Dobeson, Mark Baxter, Tom Roques, Alexander Pawsey, Roderick Oakes, Lucinda Melcher, Olivia Chan, Sarah Ayers, Helen Bowyer, Mohammed Althohami, Sajjan Mittal, Laura Feeney, Avinash Aujayeb, Omar Sheikh, Sangary Kathirgamakarthigeyan, Victoria K. Woodcock, Francesca Holt, Simon Wyatt, Oliver Topping, Michaël Tilby, Madhumita Bhattacharyya, Emma Burke, Shawn Ellis, Joseph Chacko, Taslima Rabbi, Michael Rowe, Rebecca Sargent, Christina Thirlwell +99 moreopenalex +1 more sourceMulti‐Omics Integration for Advancing Glioma Precision Medicine
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT
Gliomas are among the most malignant and aggressive tumors of the central nervous system, characterized by the absence of early diagnostic markers, poor prognosis, and a lack of effective treatments. Advances in high‐throughput technologies have facilitated a refined molecular classification of gliomas, incorporating genetic features. However, Maria Guarnaccia, Valentina La Cognata, Giulia Gentile, Giovanna Morello, Sebastiano Cavallaro +4 morewiley +1 more sourceCirculating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors
Frontiers in Cell and Developmental BiologyIntroduction: Clinical roles of plasma IL-6 levels have been reported in patients with various cancers, including non-small cell lung cancer (NSCLC), treated with immune checkpoint inhibitors (ICIs). However, the roles of other IL-6 signaling components, Yoshiro Nakahara, Yoshiro Nakahara, Taku Kouro, Taku Kouro, Satoru Motoyama, Satoru Motoyama, Satoru Motoyama, Masatomo Miura, Kazuma Fujita, Yuka Igarashi, Naoko Higashijima, Norikazu Matsuo, Hidetomo Himuro, Hidetomo Himuro, Feifei Wei, Feifei Wei, Shun Horaguchi, Shun Horaguchi, Shun Horaguchi, Kayoko Tsuji, Kayoko Tsuji, Yasunobu Mano, Yasunobu Mano, Mitsuru Komahashi, Mitsuru Komahashi, Mitsuru Komahashi, Haruhiro Saito, Koichi Azuma, Tetsuro Sasada, Tetsuro Sasada +29 moredoaj +1 more sourceEffect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer [PDF]
, 2023 Clelia Madeddu, Sı́lvia Busquets, Clelia Donisi, Eleonora Lai, Andrea Pretta, Francisco J. López‐Soriano, Josep M. Argilés, Mario Scartozzi, Antonio Macciò +8 moreopenalex +1 more sourceRRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1
Advanced Biology, EarlyView.The study reveals that RRP9 is abnormally highly expressed in ESCC tissues and is closely associated with poor prognosis in patients. Furthermore, it is found that RRP9 promotes ESCC progression through enhancing the E2F1‐mediated transcriptional regulation of CDK1.Gang He, Yilong Wan, Yanbo Zhu, Bo Peng, Shengxiang Shao, Xinyi Zou, Zhenyu Han, Jiaxi Li, Sheng Ju, Xin Tong, Jun Zhao, Hansi Liang, Liuqing Zhang, Jiashi Xiong, Dong Jiang +14 morewiley +1 more sourceMachine learning–based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors
Frontiers in ImmunologyIntroductionImmune checkpoint inhibitors (ICIs) targeting the programmed death-1/ligand-1 (PD-1/PD-L1) axis have significantly improved treatment outcomes in non-small cell lung cancer (NSCLC); however, challenges remain owing to the limited durability ...Feifei Wei, Feifei Wei, Hiroyuki Takeda, Koichi Azuma, Yoshiro Nakahara, Yoshiro Nakahara, Yuka Igarashi, Kenta Murotani, Haruhiro Saito, Shuji Murakami, Tetsuro Kondo, Taku Kouro, Taku Kouro, Hidetomo Himuro, Hidetomo Himuro, Kayoko Tsuji, Kayoko Tsuji, Mitsuru Komahashi, Mitsuru Komahashi, Mitsuru Komahashi, Tatsuya Sawasaki, Tetsuro Sasada, Tetsuro Sasada +22 moredoaj +1 more source
